Traitement par daratumumab (anticorps anti-CD38), une avancée thérapeutique majeure pour les patients atteints de myélome multiple mais une complexité pour les biologistes

Kumar, 2016, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, 17, e328, 10.1016/S1470-2045(16)30206-6 Noori, 2021, Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference, Clin Chem Lab Med, 59, 1963, 10.1515/cclm-2021-0399 Saltarella, 2020, Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma, Cells, 9, 167, 10.3390/cells9010167 Pojero, 2016, Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases, Cytometry B Clin Cytom, 90, 91, 10.1002/cyto.b.21269 Van de Donk, 2016, Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma, Blood, 127, 681, 10.1182/blood-2015-10-646810 Chapuy, 2016, International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing, Transfusion, 56, 2964, 10.1111/trf.13789